Larimar Therapeutics (LRMR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 10. Analyst ...

Larimar Therapeutics (NASDAQ:LRMR) on Thursday filed a prospectus related to a proposed mixed shelf offering of up to $300M. This prospectus is not an offer to sell these securities. SEC Filing More ...

First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 Positive ...

Given this risk, we thought we'd take a look at whether Larimar Therapeutics (NASDAQ:LRMR) shareholders should be worried ...

LRMR stock results show that Larimar Therapeutics missed analyst estimates for earnings per share the first quarter of ...

She showed us a heart-shaped Larimar stone pendant, and in her lovely English creole accent she told Lucy the stone is the ...

BALA CYNWYD, Pa. — BALA CYNWYD, Pa. — Larimar Therapeutics, Inc. (LRMR) on Thursday reported a loss of $14.7 million in its first quarter. On a per-share basis, the Bala Cynwyd, Pennsylvania-based ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead ...

Sweet treats are the sweetest only when we enjoy them infrequently. That's the energy of this week, between May 13 - 19, 2024 ...

BALA CYNWYD, Pa. (AP) — BALA CYNWYD, Pa. (AP) — Larimar Therapeutics, Inc. (LRMR) on Thursday reported a loss of $14.7 million in its first quarter. On a per-share basis, the Bala Cynwyd ...